Media

Bayer material innovations help improve wound care

Bayer MaterialScience is a one-stop shop for a complete range of polyurethane materials for modern wound treatment, from the protective films, to the foam, to the adjustable adhesives.

Anaheim, Calif., February 12, 2014 — Bayer MaterialScience LLC announces a polyurethane-based adhesive based on its Baymedix® A raw material is now available in the United States.

Targeted for skin adherence in wound care and biosensor applications, this skin-friendly adhesive offers adjustable adhesive strengths, hydroselectivity and gentle removal that is comparable to silicone adhesives. Additionally, Baymedix A raw material offers high breathability and is compatible with common sterilization technologies.

“This proven material has been used by leading international wound dressing brands for more than 15 years,” said Bentley Mah, Baymedix sales representative, Bayer MaterialScience LLC. “Now, we’re pleased to extend its availability to the U.S. market.”

The company will highlight this polyurethane-based adhesive, along with other developments related to wound treatment, at MD&M West, the largest medical device event in the U.S. Bayer’s range of materials for the wound care market includes polyurethane raw materials for wound dressings and thermoplastic films engineered for protective coverings.

For example, Bayer will feature its innovative aliphatic polyurethane foam based on Baymedix FP reactive foam technology. This raw material enables the production of very smooth and conformable foams that are non-yellowing – they maintain their white color over time. With high absorption rates and great fluid retention capability, these foams fit the moisture management requirements of advanced wound dressings very well.

“Today’s wound care treatment focuses on the patient’s well-being, with particular attention on accelerating healing and added protection from infection, which can be enhanced with highly breathable thermoplastic polyurethane films that act as a second skin during the healing process,” explained Chris Cooper, business development manager, Functional Films NAFTA, Bayer MaterialScience LLC. “Bayer Films, a specialty films business of Bayer MaterialScience, offers Dureflex® and Platilon® films that help meet these needs.”

The films, made from thermoplastic polyurethane, are tailor-made for use as soft, thin-film protective coverings that control water vapor transmission and are highly flexible, with a matte surface. This ensures comfortable wear and unobtrusive wound coverage.

With these products, Bayer MaterialScience is a one-stop shop for a complete range of polyurethane materials for modern wound treatment, from the protective films, to the foam, to the adjustable adhesive.

Attendees at MD&M West Conference and Exposition, Feb. 10-13 in Anaheim, Calif., can visit Bayer’s booth (#2021) for more details about Bayer’s material solutions for medical applications.

About Bayer MaterialScience LLC:

Bayer MaterialScience LLC is one of the leading producers of high-performance plastics in North America and is part of the global Bayer MaterialScience business with approximately 14,500 employees at 30 production sites around the world and 2012 sales of 11.5 billion euros. The company manufactures high-tech polymer materials and develops innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction, medical, and sports and leisure industries. Sustainability is central to Bayer MaterialScience LLC’s business and is based around the key areas of innovation, product stewardship, social responsibility and respect for the environment.

For more information about Bayer MaterialScience’s complete range of polyurethane materials for modern wound treatment, visit www.baymedix.com/.

# # #

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Use of Cookies

We would like to use cookies to detect our users’ preferences and design the website optimally. More detailed information and instructions on how you can revoke your consent at any time are provided in our settings of Data Privacy Declaration.